Literature DB >> 26489647

Transcriptomic characterization of fibrolamellar hepatocellular carcinoma.

Elana P Simon1, Catherine A Freije2, Benjamin A Farber3, Gadi Lalazar1, David G Darcy3, Joshua N Honeyman3, Rachel Chiaroni-Clarke1, Brian D Dill4, Henrik Molina4, Umesh K Bhanot5, Michael P La Quaglia6, Brad R Rosenberg7, Sanford M Simon8.   

Abstract

Fibrolamellar hepatocellular carcinoma (FLHCC) tumors all carry a deletion of ∼ 400 kb in chromosome 19, resulting in a fusion of the genes for the heat shock protein, DNAJ (Hsp40) homolog, subfamily B, member 1, DNAJB1, and the catalytic subunit of protein kinase A, PRKACA. The resulting chimeric transcript produces a fusion protein that retains kinase activity. No other recurrent genomic alterations have been identified. Here we characterize the molecular pathogenesis of FLHCC with transcriptome sequencing (RNA sequencing). Differential expression (tumor vs. adjacent normal tissue) was detected for more than 3,500 genes (log2 fold change ≥ 1, false discovery rate ≤ 0.01), many of which were distinct from those found in hepatocellular carcinoma. Expression of several known oncogenes, such as ErbB2 and Aurora Kinase A, was increased in tumor samples. These and other dysregulated genes may serve as potential targets for therapeutic intervention.

Entities:  

Keywords:  fusion gene; genomics; liver cancer; pediatric cancer; protein kinase

Mesh:

Year:  2015        PMID: 26489647      PMCID: PMC4640752          DOI: 10.1073/pnas.1424894112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  103 in total

1.  Regulation of transcription by cyclic AMP-dependent protein kinase.

Authors:  P L Mellon; C H Clegg; L A Correll; G S McKnight
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

2.  The control of glycolysis and gluconeogenesis by protein phosphorylation.

Authors:  H G Hers
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1983-07-05       Impact factor: 6.237

3.  PKA phosphorylation couples hepatic inositol-requiring enzyme 1alpha to glucagon signaling in glucose metabolism.

Authors:  Ting Mao; Mengle Shao; Yifu Qiu; Jialiang Huang; Yongliang Zhang; Bo Song; Qiong Wang; Lei Jiang; Yi Liu; Jing-Dong J Han; Pengrong Cao; Jia Li; Xiang Gao; Liangyou Rui; Ling Qi; Wenjun Li; Yong Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-12       Impact factor: 11.205

4.  Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.

Authors:  Joshua N Honeyman; Elana P Simon; Nicolas Robine; Rachel Chiaroni-Clarke; David G Darcy; Irene Isabel P Lim; Caroline E Gleason; Jennifer M Murphy; Brad R Rosenberg; Lydia Teegan; Constantin N Takacs; Sergio Botero; Rachel Belote; Soren Germer; Anne-Katrin Emde; Vladimir Vacic; Umesh Bhanot; Michael P LaQuaglia; Sanford M Simon
Journal:  Science       Date:  2014-02-28       Impact factor: 47.728

5.  DICKKOPF-4 and -2 genes are upregulated in human colorectal cancer.

Authors:  Akira Matsui; Tatsuya Yamaguchi; Shinya Maekawa; Chikako Miyazaki; Shinichi Takano; Tomoyoshi Uetake; Taisuke Inoue; Masahiko Otaka; Hiroyuki Otsuka; Tadashi Sato; Atsuya Yamashita; Yuka Takahashi; Nobuyuki Enomoto
Journal:  Cancer Sci       Date:  2009-07-02       Impact factor: 6.716

6.  The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients.

Authors:  David G Darcy; Rachel Chiaroni-Clarke; Jennifer M Murphy; Joshua N Honeyman; Umesh Bhanot; Michael P LaQuaglia; Sanford M Simon
Journal:  Oncotarget       Date:  2015-01-20

7.  Protein kinase A activation enhances β-catenin transcriptional activity through nuclear localization to PML bodies.

Authors:  Mei Zhang; Emilia Mahoney; Tao Zuo; Parmeet K Manchanda; Ramana V Davuluri; Lawrence S Kirschner
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

8.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

9.  GSVA: gene set variation analysis for microarray and RNA-seq data.

Authors:  Sonja Hänzelmann; Robert Castelo; Justin Guinney
Journal:  BMC Bioinformatics       Date:  2013-01-16       Impact factor: 3.169

10.  Activation of NF-kappa B in vivo is regulated by multiple phosphorylations.

Authors:  M Naumann; C Scheidereit
Journal:  EMBO J       Date:  1994-10-03       Impact factor: 11.598

View more
  52 in total

1.  Cytoreductive Surgery and HIPEC for Recurrent Fibrolamellar Hepatocellular Carcinoma with Peritoneal Carcinomatosis.

Authors:  D Kyziridis; A Kalakonas; K Zarambouka; C Hristakis; Antonios-Apostolos K Tentes
Journal:  J Gastrointest Cancer       Date:  2020-03

Review 2.  Next-Generation Sequencing Strategies.

Authors:  Shawn E Levy; Braden E Boone
Journal:  Cold Spring Harb Perspect Med       Date:  2019-07-01       Impact factor: 6.915

3.  Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.

Authors:  Imane El Dika; Anita S Bowman; Michael F Berger; Marinela Capanu; Joanne F Chou; Ryma Benayed; Ahmet Zehir; Jinru Shia; Eileen M O'Reilly; David S Klimstra; David B Solit; Ghassan K Abou-Alfa
Journal:  Cancer       Date:  2020-07-14       Impact factor: 6.860

Review 4.  Targeting cholangiocarcinoma.

Authors:  Joachim C Mertens; Sumera Rizvi; Gregory J Gores
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-08-24       Impact factor: 5.187

5.  DNAJB1-PRKACA fusion kinase interacts with β-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma.

Authors:  Edward R Kastenhuber; Gadi Lalazar; Shauna L Houlihan; Darjus F Tschaharganeh; Timour Baslan; Chi-Chao Chen; David Requena; Sha Tian; Benedikt Bosbach; John E Wilkinson; Sanford M Simon; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-21       Impact factor: 11.205

6.  Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion.

Authors:  Rondell P Graham; Carolin Lackner; Luigi Terracciano; Yessica González-Cantú; Joseph J Maleszewski; Patricia T Greipp; Sanford M Simon; Michael S Torbenson
Journal:  Hepatology       Date:  2018-05-11       Impact factor: 17.425

7.  Intracranial metastasis in fibrolamellar hepatocellular carcinoma.

Authors:  William J Hammond; Gadi Lalazar; James A Saltsman; Benjamin A Farber; Enrico Danzer; Tshering C Sherpa; Charles D Banda; Jeffrey R Andolina; Sasan Karimi; Cameron W Brennan; Michael S Torbenson; Michael P La Quaglia; Sanford M Simon
Journal:  Pediatr Blood Cancer       Date:  2017-12-29       Impact factor: 3.167

8.  Hotspots of Aberrant Enhancer Activity in Fibrolamellar Carcinoma Reveal Candidate Oncogenic Pathways and Therapeutic Vulnerabilities.

Authors:  Timothy A Dinh; Ramja Sritharan; F Donelson Smith; Adam B Francisco; Rosanna K Ma; Rodica P Bunaciu; Matt Kanke; Charles G Danko; Andrew P Massa; John D Scott; Praveen Sethupathy
Journal:  Cell Rep       Date:  2020-04-14       Impact factor: 9.423

9.  Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma.

Authors:  Suguru Yamashita; Jean-Nicolas Vauthey; Ahmed O Kaseb; Thomas A Aloia; Claudius Conrad; Manal M Hassan; Guillaume Passot; Kanwal P Raghav; Mohamed A Shama; Yun Shin Chun
Journal:  J Gastrointest Surg       Date:  2016-07-25       Impact factor: 3.452

10.  Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.

Authors:  Ghassan K Abou-Alfa; Robert Mayer; Alan P Venook; Allison F O'Neill; Muhammad S Beg; Michael LaQuaglia; Peter T Kingham; Rachel Kobos; Olca Basturk; Cameron Brennan; Adam Yopp; James J Harding; Stephen Leong; John Crown; Emir Hoti; Gregory Leonard; Michele Ly; Mikaela Bradley; Emily Valentino; David Markowitz; Alexander Zukiwski; Ken Ren; John D Gordan
Journal:  Oncologist       Date:  2020-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.